Latest Conference Articles

August 7th 2022, 2:33pm

IASLC World Conference on Lung Cancer

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.

August 7th 2022, 1:30pm

IASLC World Conference on Lung Cancer

Four distinct subgroups, each associated with distinctive signaling pathways, microenvironments, and clinical-pathologic futures, were discovered in a population of patients with MET exon 14 skipping non–small cell lung cancer.

August 7th 2022, 11:21am

IASLC World Conference on Lung Cancer

Sugemalimab appeared to be safe and effective when used as consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) who did not have disease progression following concurrent chemoradiation or sequential chemoradiation.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The combination use of first-line durvalumab plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer improved overall survival compared with standard-of-care chemotherapy.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Larotrectinib continued to elicit durable responses and a low toxicity profile in patients with NTRK fusion–positive lung cancer, according to long-term follow-up data from the phase 2 NAVIGATE trial and phase 1 LOXO-TRK-14001 trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Ociperlimab, an anti-TIGIT monoclonal antibody, plus the anti–PD-L1 monoclonal antibody tislelizumab induced promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer, according to data from the dose-expansion cohort of the AdvanTIG-105 trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The addition of tremelimumab to durvalumab and chemotherapy improved clinical benefit and survival benefit vs. chemotherapy alone in patients with PD-L1–negative metastatic non–small cell lung cancer.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Second- or third-line tislelizumab continued to display an overall survival benefit vs docetaxel in patients with non–small cell lung cancer.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Investigators are evaluating the combination of repotrectinib and osimertinib for the treatment of patients with advanced or metastatic EGFR-mutant non–small cell lung cancer in the phase 1 TOTEM trial.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

August 6th 2022, 10:00am

IASLC World Conference on Lung Cancer

The antibody-drug conjugate sacituzumab govitecan will be evaluated vs single-agent docetaxel during the phase 3 EVOKE-01 trial in patients with metastatic non–small cell lung cancer.

August 5th 2022, 7:41pm

IASLC World Conference on Lung Cancer

Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.

August 2nd 2022, 9:50pm

IASLC World Conference on Lung Cancer

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.

July 30th 2022, 8:42pm

International Congress on the Future of Breast Cancer West

As ongoing research efforts are shifting further into personalized care, Hope S. Rugo, MD, FASCO discusses how pathologic complete response and the predictive value of residual cancer burden scoring are becoming a pivotal end point for the changing triple-negative breast cancer landscape.

July 30th 2022, 8:04pm

International Congress on the Future of Breast Cancer West

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

July 30th 2022, 6:51pm

International Lung Cancer Congress

Roy S. Herbst, MD, PhD, discusses the importance of evaluating ways of altering tumor host factors to improve response to immunotherapy in patients with lung cancer.

July 30th 2022, 3:05pm

International Lung Cancer Congress

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

July 30th 2022, 2:50pm

International Lung Cancer Congress

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

July 30th 2022, 2:00pm

International Lung Cancer Congress

Daniel Morgensztern, MD, discusses updates on the investigation of bispecific antibodies and bispecific T-cell engagers in non–small cell lung cancer and small cell lung cancer.

July 30th 2022, 12:00pm

International Lung Cancer Congress

Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.